Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JOHN W. who wrote (3191)	12/7/1997 2:12:00 PM
From: Oliver & Co	Read Replies (2) of 6136

Amprenavir is the trade name for 141W94. It is a potent, and highly bioavailabe HIV-1 Protease Inhibitor currently in phase III clinical trials. Phase I/II trials have demonstrated that it can suppress plasma HIV-1 RNA levels to 1.5 to 2.0 log10 below baseline when given as monotherapy (not good enough IMHO). It is also able to drive RNA levels below the limit of detection in most patients when given with either 1592(abacavir), or AZT/3TC. The drug is well tolerated. Major toxicities are mild nausea, occasional diarrhea and rash. Grade 3 or 4 rashes seen in ~2% of patients. There is cross-resistance with other PIs. Best response when used in combination with other PIs. IMHO, not as good as Nelf, or Cryx. There should be a place in our bag for this drug, in about 1 year. But very limited. I expect Glaxo to scream in Jan at the antiretrovirals meeting, AZT get a recomendation, not to be used as initial therapy. <I bought another 1K shares of AGPH on Friday at 30.625> That is how sure I am about this Co. Good Sunday. JLL

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next